Investigating gamma oscillation therapy for Alzheimer's Disease
Sensory-Evoked Cortical Gamma Oscillation: Impact on Visual Processing and Cognitive Function in Patients With Alzheimer's Disease
NA · University of Tennessee Medical Center · NCT05206305
This study is testing a new sensory device that uses sound to see if it can improve thinking and sensory skills in people with Alzheimer's Disease.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | University of Tennessee Medical Center (other) |
| Locations | 1 site (Knoxville, Tennessee) |
| Trial ID | NCT05206305 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of a sensory stimulation device that evokes 40-Hz gamma oscillations on cognitive function and sensory processing in patients with Alzheimer's Disease. Participants will undergo assessments of cognitive function and cortical network activity using electroencephalography (EEG) and event-related potentials (ERP) before and after an 8-week treatment period. The study will explore both immediate and long-term effects of the therapy, as well as the relationship between neurophysiological changes and cognitive improvements.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 60 and older with a confirmed diagnosis of Alzheimer's Disease who can provide informed consent.
Not a fit: Patients with severe dementia or other significant medical conditions that impair cognitive abilities may not benefit from this study.
Why it matters
Potential benefit: If successful, this therapy could enhance cognitive function and sensory processing in Alzheimer's Disease patients.
How similar studies have performed: While this approach is innovative, similar studies exploring gamma oscillation therapies have shown promising results in cognitive enhancement.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals ages 60 and older with established diagnosis of Alzheimer's Disease as defined by the current consensus criteria for AD (Albert et al, 2011, Jack et al, 2011; McKhann et al, 2011) * Fluent and literate in English language * Able to consent for themselves based upon the MacArthur Competence Assessment Tool for Clinical Research * Patients with a pre-existing positive A(beta)-PET and/or CSF tau/A(beta) markers or willingness to undergo a Lumbar Puncture (LP) with these results Exclusion Criteria: * Not fluent and literate in English * Severe dementia * Other medical conditions/neurodegenerative disease that could significantly impair cognitive abilities * Cardiac pacemakers or any other implants that may not be compatible with MRI * Cognitively impaired to the point the patient is unable to consent for themselves * Claustrophobic to the point that medication is required
Where this trial is running
Knoxville, Tennessee
- University of Tennessee Medical Center — Knoxville, Tennessee, United States (RECRUITING)
Study contacts
- Principal investigator: Roberto Fernandez-Romero, MD — University of Tennessee Medical Center
- Study coordinator: Roberto Fernandez-Romero, MD
- Email: rfernandez@utmck.edu
- Phone: 865-305-7242
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Alzheimer Disease